GB0809360D0 - Calcium modulation - Google Patents

Calcium modulation

Info

Publication number
GB0809360D0
GB0809360D0 GBGB0809360.1A GB0809360A GB0809360D0 GB 0809360 D0 GB0809360 D0 GB 0809360D0 GB 0809360 A GB0809360 A GB 0809360A GB 0809360 D0 GB0809360 D0 GB 0809360D0
Authority
GB
United Kingdom
Prior art keywords
calcium modulation
modulation
calcium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0809360.1A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oxford University Innovation Ltd
Original Assignee
Oxford University Innovation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxford University Innovation Ltd filed Critical Oxford University Innovation Ltd
Priority to GBGB0809360.1A priority Critical patent/GB0809360D0/en
Publication of GB0809360D0 publication Critical patent/GB0809360D0/en
Priority to PCT/GB2009/001295 priority patent/WO2009141627A1/en
Ceased legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/12Ketones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415Pyridoxine, i.e. Vitamin B6
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • A61K31/522Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/59Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/5939,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
GBGB0809360.1A 2008-05-22 2008-05-22 Calcium modulation Ceased GB0809360D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB0809360.1A GB0809360D0 (en) 2008-05-22 2008-05-22 Calcium modulation
PCT/GB2009/001295 WO2009141627A1 (en) 2008-05-22 2009-05-22 Treating niemann-pick disease type c and related disorders by elevating intracellular calcium

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0809360.1A GB0809360D0 (en) 2008-05-22 2008-05-22 Calcium modulation

Publications (1)

Publication Number Publication Date
GB0809360D0 true GB0809360D0 (en) 2008-07-02

Family

ID=39615951

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0809360.1A Ceased GB0809360D0 (en) 2008-05-22 2008-05-22 Calcium modulation

Country Status (2)

Country Link
GB (1) GB0809360D0 (en)
WO (1) WO2009141627A1 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR122019024895B8 (en) * 2008-06-26 2021-07-27 Orphazyme As use of a bioactive agent capable of increasing the intracellular concentration of hsp70
AU2011335545A1 (en) 2010-11-30 2013-06-13 Orphazyme Aps Methods for increasing intracellular activity of Hsp70
EP2758403B1 (en) 2011-09-21 2016-04-27 Inception Orion, Inc. Tricyclic compounds useful as neurogenic and neuroprotective agents
CN104812737A (en) * 2012-05-08 2015-07-29 塞利克斯比奥私人有限公司 Compositions and methods for treatment of hyperglycemia
EP2906570A4 (en) * 2012-10-15 2016-06-08 Yeda Res & Dev Use of sphingoid long chain bases and their analogs in treating and preventing bacterial infections
EP2968300A4 (en) * 2013-03-15 2016-09-28 Unither Virology Llc Antibacterial compounds
MX2015016771A (en) 2013-06-25 2016-03-31 Squibb Bristol Myers Co Carbazole carboxamide compounds useful as kinase inhibitors.
TWI648272B (en) 2013-06-25 2019-01-21 美商必治妥美雅史谷比公司 Substituted tetrahydrocarbazole and carbazole carbamide compounds
BR112017004948A2 (en) 2014-09-15 2017-12-05 Orphazyme Aps pharmaceutical formulation.
BR112017007563A2 (en) 2014-10-24 2017-12-19 Bristol Myers Squibb Co tricyclic atropisomers compounds
SG10201903578VA (en) 2014-10-24 2019-05-30 Bristol Myers Squibb Co Indole carboxamides compounds useful as kinase inhibitors
EA032361B1 (en) 2014-10-24 2019-05-31 Бристол-Майерс Сквибб Компани Tricyclic compounds
WO2016110702A1 (en) * 2015-01-07 2016-07-14 Isis Innovation Limited Treatment of mycobacterial infection
WO2016210116A1 (en) * 2015-06-25 2016-12-29 Lysosomal Therapeutics Inc. Methods and compositions for treating lysosomal storage disorders
WO2016210120A1 (en) * 2015-06-25 2016-12-29 Lysosomal Therapeutics Inc. Methods and compositions for treating neurodegenerative disorders
US10898476B2 (en) 2016-04-13 2021-01-26 Orphazyme A/S Heat shock proteins and cholesterol homeostasis
US20190111041A1 (en) 2016-04-29 2019-04-18 Orphazyme A/S Arimoclomol for treating glucocerebrosidase associated disorders
EP3323415A1 (en) * 2016-11-16 2018-05-23 Institut du Cerveau et de la Moelle Epiniere-ICM Treatment of neurodegenerative diseases
IL260690A (en) 2018-07-19 2018-12-31 Yeda Res & Dev Sphingosine analogs and use thereof against bacterial lung infections
EP3952859A4 (en) * 2019-04-12 2023-05-10 Loma Linda University Methods for treatment of niemann-pick disease type c
KR20230128462A (en) 2020-11-19 2023-09-05 제브라 덴마크 에이/에스 Process for preparing arimoclomol citrate and intermediates thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1126832A2 (en) * 1998-10-27 2001-08-29 Yale University Conductance of improperly folded proteins through the secretory pathway
US20040266883A1 (en) * 1999-10-27 2004-12-30 Yale University Conductance of improperly folded proteins through the secretory pathway and related methods for treating disease

Also Published As

Publication number Publication date
WO2009141627A1 (en) 2009-11-26

Similar Documents

Publication Publication Date Title
GB0809360D0 (en) Calcium modulation
TWI316121B (en) Lamp
TWI349087B (en) Lamp
TWI367207B (en) Substituted pyrrolidine-2-carboxamides
EG26153A (en) Absorbents
AU324520S (en) Shoes
AU322403S (en) Lamp
GB0904436D0 (en) Engagement arrangement
TWI349085B (en) Lamp
EP2192916A4 (en) Modulation of synaptogenesis
GB0801032D0 (en) Immune modulation
IL208281A0 (en) Substituted cyclohexyldiamines
IL209175A0 (en) Substituted qunazolines
GB0806046D0 (en) Lamp
GB0808886D0 (en) Dual purpose modulator
GB2460543B (en) Flange spreader
IL190168A0 (en) Orthopedic shoe
SI2180242T1 (en) Lamp
GB0810084D0 (en) Eqne trainign aid
GB2457967B (en) Modulation scheme
GB0806468D0 (en) Mind plan
GB0811938D0 (en) Pintagram or Drinkagram
GB0804677D0 (en) Shoe
AU324522S (en) Shoes
AU319955S (en) Lamp

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)